Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Petrylak Discusses the Future of Abiraterone Acetate

April 27th 2012

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Future of Abiraterone Acetate

Dr. Sartor on Combining Radium-223 and Provenge

April 25th 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge

Dr. Sandler Describes the RTOG 9408 Trial Results

April 23rd 2012

Dr. Howard Sandler, from Cedars-Sinai Medical Center, Describes the RTOG 9408 Prostate Cancer Trial Results

Dr. Gomella Suggests Provenge Benefit Understated

April 20th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Examines the Understating of Provenge Benefits

"Scotty, I Need More Power"

April 20th 2012

The paradigm of "more energy is better" is not limited to space travel, and in fact is center stage in a growing debate in the field of radiation oncology.

Revised View Enhances Provenge OS Data

April 19th 2012

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

Dr. Dreicer on Sequencing MDV3100 and Abiraterone

April 18th 2012

Dr. Robert Dreicer, from the Cleveland Clinic, Discusses Sequencing MDV3100 and Abiraterone

April 2012: Trials in Progress

April 17th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Gomella Discusses Informed Patient Decisions

April 16th 2012

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on Helping Patients Make Informed Medical Decisions

Dr. Crawford on Transperineal 3D Mapping Biopsy

April 13th 2012

Dr. David Crawford, from University of Colorado Health Sciences Center, Discusses Transperineal 3D Mapping Biopsy

Insights From Genomic Approaches to Oncology Discovery

April 12th 2012

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Dr. Petrylak on Chemotherapy in Prostate Cancer

April 11th 2012

Dr. Daniel Petrylak, from Columbia University Medical Center, Discusses Chemotherapy in Prostate Cancer

Bone Microenvironment Promotes Bone Metastases in Prostate Cancer

April 10th 2012

Targeting the bone microenvironment appears to be a potential approach to treating prostate cancer.

Dr. Gomella Discusses the Challenges of PSA Screening

April 5th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the Challenges of PSA Screening

Dr. Sartor on Radium-223 in Early Prostate Cancer

April 4th 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Radium-223 in Early Prostate Cancer

Dr. Dreicer Discusses Using Abiraterone Acetate

April 3rd 2012

Dr. Robert Dreicer, from the Taussig Cancer Institute at the Cleveland Clinic, Discusses Using Abiraterone Acetate

Current State of the Art for Treatment of Prostate Cancer

April 3rd 2012

An interview with Nicholas J. Vogelzang, MD, during the ASCO 2012 Genitourinary Cancers Symposium, about treatment of prostate cancer and unmet needs.

EBRT More Toxic, Costly Than Radical Prostatectomy or Brachytherapy

April 2nd 2012

EBRT led to more long-term toxicity and higher treatment-related costs compared with radical prostatectomy or brachyherapy.

Dr. Mohile On Prostate Cancer in Elderly Patients

March 30th 2012

Dr. Supriya Mohile from the University of Rochester Medical Center Discusses Prostate Cancer in Elderly Patients

Trial Affirms Survival Benefit of Novel Antiandrogen Signaling Agent MDV3100 in Advanced Prostate Cancer

March 30th 2012

The investigational agent MDV3100 extended survival in men with late-stage castration-resistant prostate cancer in the phase III AFFIRM trial.